Jubbonti

Jubbonti is a medicine used to treat the following conditions: - osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause, Jubbonti reduces the risk of fractures in the spine and elsewhere in the body, including in the hip; - bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Jubbonti reduces the risk of fractures in the spine; - bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection. Jubbonti is a biological medicine and contains the active substance denosumab. It is a ‘biosimilar medicine’; this means that Jubbonti is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Jubbonti is Prolia. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines).